$ARVN News
Last published 1d ago
- 1d agoARVNArvinas to Present at Jefferies Global Healthcare ConferenceGlobeNewswireNEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 18 at 9:00 a.m. GMT/4:00 a.m. EST.
- 1w agoARVNArvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual MeetingGlobeNewswire– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refractory non-Hodgkin
- 1w agoARVNARVINAS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoARVNArvinas Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase
- 1w agoARVNARVN 3Q26 Earnings Call - ARVINAS INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the RVNES Q3 2026 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. To ask a question durin
- 2w agoARVNArvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein DegradationGlobeNewswire– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in
- 2w agoARVNArvinas to Report Third Quarter 2026 Financial Results on November 3, 2026GlobeNewswireNEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 1mo agoARVNArvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s DiseaseGlobeNewswire– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in
- 1mo agoARVNArvinas - Morgan Stanley 24th Annual Global Healthcare Conference - ARVINAS INCEarnings Call TranscriptsGreat. Thanks for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com backslash research
- 1mo agoARVNArvinas - 1773836 - ARVINAS INCEarnings Call TranscriptsGreat. Thanks for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com backslash research
- 2mo agoARVNWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ARVINAS INCEarnings Call TranscriptsAll right, everybody. I think we'll get started here with our next fireside discussion. So my name is Derek Archula, one of the Wells Fargo biotech analysts. With us now, we have Arvinas from the company. We have Randy T
- 2mo agoARVNArvinas to Participate in Upcoming Investor ConferencesGlobeNewswireNEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted
- 2mo agoARVNArvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted
- 3mo agoARVNARVN 2Q26 Earnings Call - ARVINAS INCEarnings Call TranscriptsHello, and welcome to our Venus Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To as
- 3mo agoARVNArvinas Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical
- 3mo agoARVNArvinas to Report Second Quarter 2026 Financial Results on August 4, 2026GlobeNewswireNEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review
- 5mo agoARVNArvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's DiseaseGlobeNewswireNEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the
- 5mo agoARVNArvinas to Present at Jefferies Global Healthcare ConferenceGlobeNewswireNEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 5mo agoARVNArvinas Employees Give Back During Company-wide Impact DayGlobeNewswireNEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that
- 6mo agoARVNARVN 1Q26 Earnings Call - ARVINAS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Arena's first quarter 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answ
- 6mo agoARVNArvinas Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast
- 6mo agoARVNPFEArvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)GlobeNewswire– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW
- 6mo agoARVNArvinas to Report First Quarter 2026 Financial Results on May 12, 2026GlobeNewswireNEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will
- 6mo agoARVNPFEArvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast CancerGlobeNewswire– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track
- 6mo agoARVNApproval of Veppanu, Nda #219835 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 05/01/2026; Drug Name: Veppanu, Nda #219835; Active Ingredients: VEPDEGESTRANT; Company: Arvinas Operations Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 219835
- 8mo agoARVNArvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase
- 8mo agoARVNArvinas to Participate in Upcoming Investor ConferencesGlobeNewswireNEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 8mo agoARVNArvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewswireNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 9mo agoARVNArvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and DirectorGlobeNewswire– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE
- 9mo agoARVNPFEPROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsightPR NewswireDelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of...
- 11mo agoARVNArvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and ExpositionGlobeNewswire– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation
- 11mo agoARVNArvinas to Present at Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireNEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah
- 11mo agoARVNPFEArvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)GlobeNewswireNEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple
- 1y agoARVNArvinas Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated
- 1y agoARVNArvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual MeetingGlobeNewswireNEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 1y agoARVNArvinas to Participate in Upcoming Investor ConferencesGlobeNewswireNEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 1y agoARVNArvinas to Report Third Quarter 2025 Financial Results on November 5, 2025GlobeNewswireNEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 1y agoARVNArvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswire– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differentiation of
- 1y agoARVNArvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireNEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 1y agoARVNPFEPatient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based TherapyGlobeNewswire– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to
- 1y agoARVNPFEArvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) CongressGlobeNewswire– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) today announced that new
- 1y agoARVNArvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®GlobeNewswire– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects in both trials –
- 1y agoARVNArvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®GlobeNewswireNEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two
- 1y agoARVNPFEArvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value CreationGlobeNewswireArvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million
- 1y agoARVNArvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoARVNArvinas to Participate in Upcoming Investor ConferencesGlobeNewswireNEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
- 1y agoARVNPFEArvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast CancerGlobeNewswire– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the
- 1y agoARVNArvinas, Inc. (ARVN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoARVNArvinas Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers;
- 1y agoARVNArvinas to Report Second Quarter 2025 Financial Results on August 6, 2025GlobeNewswireNEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that